Find an MSK Doctor or Cancer Specialist
Andrew D. Seidman, MD

Andrew D. Seidman, MD

Breast Medical Oncologist

My Role at MSK

Areas of Expertise

My Specialties

  • Breast Cancer
View all
Dr. Seidman's Office Information
Languages: English
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
English
Share

About Me

What I Do at MSK
  • Attending Physician
Get To Know Me

I am an experienced medical oncologist who has spent three decades caring for people with breast cancer. I specialize in treating all subtypes and stages of breast cancer, from the earliest to the most advanced stages of the disease. I have special expertise in the understanding and treatment of breast cancer that has metastasized (spread) to the brain, a condition that has historically been managed primarily by radiation oncologists and neurosurgeons.

I typically see more than 1,000 patients each year, both remotely and in person. The pandemic has taught us that we can treat patients’ disease and improve well-being both ways, but I much prefer to see patients in person.

Read more

Patients and their loved ones are naturally concerned about how breast cancer will affect their survival and quality of life. The large amount of information available on the internet often leads people to feel overwhelmed and confused. My goal is to provide them with expert, evidence-based guidance in terms of diagnosis, prognosis, and treatment, along with humane and compassionate care. I trust that this, along with the tremendously skilled team that works with me, reassures patients and leaves them feeling hopeful, optimistic, realistic, and secure in the knowledge that they are in capable and caring hands here at Memorial Sloan Kettering Cancer Center (MSK).

For me, oncology, more than any other specialty, demands a deep understanding of physiology, genetics/genomics, and humanity — and represents a great unmet need. Meaningful and rewarding patient experiences during my residency in internal medicine, an early exposure to outpatient medical oncology practice, and strong role models were important factors in my decision to become an oncologist.

Outcomes for people with breast cancer have steadily improved over the past 30 years, thanks to a tremendous increase in the understanding of underlying biology that has informed advances in surgical, medical, and radiation treatment. As the last chemotherapy drug for breast cancer was introduced well over a decade ago, there has been a shift away from conventional toxic chemotherapy to targeted therapies, which generally have fewer side effects. It has been exciting for me to be a part of this movement by designing and leading phase 1, 2, and 3 clinical trials.

My research has focused on studying new chemotherapeutic agents and targeted drugs for the treatment of metastatic breast cancer. Over the past decade, I have worked to identify better medical therapies to improve outcomes for people with breast cancer metastasis to the brain. I continue to lead and engage in interdisciplinary research in this area with my colleagues at MSK and beyond. These ongoing efforts will likely lead to changes in the way patients are treated in coming years.

Overall, I subscribe to a “work hard, play hard” philosophy! In my spare time, I enjoy biking, hiking, skiing, gardening, baking, and reading. I recently organized a book club that meets every three months, which has been especially enjoyable. I cherish the time I get to spend with my family and look forward to being able to travel more easily to see the world as the pandemic subsides.

My Role at MSK

A breast medical oncologist is a cancer doctor who specializes in breast cancer.

Areas of Expertise

My Specialties

  • Breast Cancer
Education & Honors

Education

  • MD, Hahnemann University School of Medicine

Residencies

  • Internal Medicine - Pennsylvania Hospital

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)

Fellowships

  • Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA and NYC retirees only)

In Network Coverage Type
PPO

Anthem BCBS and other BCBS licensee plans

In Network Coverage Type
PPO, POS, EPO, HMO

See updates

Anthem BCBS Health Plus

In Network Coverage Type
HMO

See updates

Anthem Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

See updates

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

See updates

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

See updates

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

See updates

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

See updates

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

See updates

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking
New Patients
Scheduling an appointment is easy. Click or call 833-305-1338— we’re available 24 hours a day, 7 days a week
Make an Appointment
Current Patients
Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Seidman sees patients at one location.

Office Phone
Location
New York, NY
Evelyn H. Lauder Breast Center
300 East 66th Street Floors 1 - 4 New York NY 10065
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Rachel Motzer. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.

See all Breast Medicine Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang KL, Humm JL, Holodny A, Beal K, Schöder H, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat 2021. 

Seidman AD, Maues J, Tomlin T, Bhatnagar V, Beaver JA. The evolution of clinical trials in metastatic breast cancer: Design features and endpoints that matter. Am Soc Clin Oncol Educ Book 40:1-11, 2020.  

Tripathy D, Cortes J, Seidman AD, et al. ATTAIN: Etirinotecan Pegol Versus Treatment of Physician’s Choice in Patients with Breast Cancer and Brain Metastases. Future Oncology 15(19):2211-25, 2019. 

Seidman AD, Bordeleau L, Fehrenbacher L et al. National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. J Clin Oncol 36(32):3259-68, 2018. Special Article 

Morikawa A, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD. Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer with brain metastasis in the era of HER-2 targeted therapy: An argument for earlier detection. Clin Breast Cancer 18(5):353-361, 2018. 

Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncol 17(2):289-95, 2015.

Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, Akram M, Nehhozina T, Jhaveri KL, Hudis CA, Seidman AD.  Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.  Ann Oncol 22(12):2597-603, 2011.

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.  J Clin Oncol 26(10):1642-1649, 2008. 

Publications on PubMed

Visit PubMed for a full listing of Dr. Seidman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrew D. Seidman discloses the following relationships and financial interests:

  • 3D Communications
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Cancer Expert Now, Inc.
    Professional Services and Activities
  • Eli Lilly and Company
    Professional Services and Activities
  • Exact Sciences Corporation
    Professional Services and Activities
  • G1 Therapeutics
    Professional Services and Activities
  • Genentech
    Professional Services and Activities
  • Gilead Sciences, Inc.
    Professional Services and Activities
  • Hackensack University Medical Center
    Professional Services and Activities
  • Mashup Media, LLC
    Professional Services and Activities
  • Merck & Co Inc.
    Professional Services and Activities
  • myMedEd, Inc.
    Professional Services and Activities
  • Novartis
    Professional Services and Activities
  • PSI Pharma Support America
    Professional Services and Activities
  • SMB Consulting
    Professional Services and Activities
  • Stemline Therapeutics, Inc.
    Professional Services and Activities
  • Virginia Oncology Associates
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: